Stocks News

LAST PRICE
820.3400
TODAY'S CHANGE (%)
Trending Up5.2800 (0.6478%)

Bid / Lots
812.0000/ 1
Ask / Lots
824.0000/ 12
Open / Previous Close
818.8000 / 815.0600
Day Range
Low 811.1000
High 826.2100
52 Week Range
Low 424.0100
High 826.2100
Volume
4,472,119
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO(R) Annual Meeting, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
  Companies Mentioned: LLY
  
  undertakes no duty to update forward-looking statements to reflect events after the date of this release.
  
  (1) Canon J. et al. Nature 2019, 575, 217-223
  
  (2) Salem M. et al. Ann Oncol 2021, 32 (3 Suppl): S218
May 30, 2024
- Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740, from 8:32AM ET on Thursday May 30, 2024 by MT Newswires
  8:32AM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: LLY
  08:32 AM EDT, 05/30/2024 (MT Newswires) -- Eli Lilly (LLY) has an average outperform rating and a price target range of $540 to $1,023, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from maj...
May 29, 2024
- Eli Lilly's Retevmo Gets FDA Accelerated Approval for Kids With RET-altered Thyroid Cancer, Solid Tumors, from 1:45PM ET on Wednesday May 29, 2024 by MT Newswires
  1:45PM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: LLY
  01:45 PM EDT, 05/29/2024 (MT Newswires) -- Eli Lilly's (LLY) Retevmo, or selpercatinib, was granted accelerated approval by the US Food and Drug Administration to treat pediatric patients two years of age and older with RET-altered thyroid cancer or...
- DJ Nvidia Stock Jumped After Stock-Split News. These 14 Names Could Be Next. -- Barrons.com, from 10:52AM ET on Wednesday May 29, 2024 by Dow Jones
  10:52AM ET on Wednesday May 29, 2024 by Dow Jones
  Companies Mentioned: LLY, AVGO, NVDA, CMG, AZO
  
  By Jacob Sonenshine
  
  Nvidia's stock split is likely just the start of more of the same from other companies. Investors should pay attention because splits often precede big rallies.
- Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases, from 6:00AM ET on Wednesday May 29, 2024 by Dow Jones
  6:00AM ET on Wednesday May 29, 2024 by Dow Jones
  Companies Mentioned: LLY
  
  Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
  
  PR Newswire
  
  GENEVA, May 29, 2024
  
  New $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India

May 31, 2024
- Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal, from 4:45PM ET on Friday May 31, 2024 by MT Newswires
  4:45PM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: AZN, FUSN
- Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints, from 9:23AM ET on Friday May 31, 2024 by MT Newswires
  9:23AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: NVS
- Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday, from 9:19AM ET on Friday May 31, 2024 by MT Newswires
  9:19AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: IBB, XLV, ABBV, VEEV, SMMT
- Novartis Confirms Long-term Safety, Efficacy of Skin Disease Drug, from 9:03AM ET on Friday May 31, 2024 by MT Newswires
  9:03AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: NVS
- Sector Update: Health Care, from 8:58AM ET on Friday May 31, 2024 by MT Newswires
  8:58AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: MRK, SMMT
- AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate, from 4:34AM ET on Friday May 31, 2024 by MT Newswires
  4:34AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: ABBV
May 30, 2024
- US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected, from 4:09PM ET on Thursday May 30, 2024 by MT Newswires
  4:09PM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: MRK, CRM, SMMT
- Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar, from 3:46PM ET on Thursday May 30, 2024 by MT Newswires
  3:46PM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: MRK, SMMT
- Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target, from 8:23AM ET on Thursday May 30, 2024 by MT Newswires
  8:23AM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: NVS
- Goldman Sachs Starts AstraZeneca With Buy Rating, $97 Price Target, from 8:14AM ET on Thursday May 30, 2024 by MT Newswires
  8:14AM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: AZN

Eli Lilly and Co
NYSE:LLYUnited States

Search Criteria

Yesterday

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO(R) Annual Meeting, from 17 hours ago by Dow Jones

May 30, 2024

Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740, from 8:32AM ET on Thursday May 30, 2024 by MT Newswires

May 29, 2024

Eli Lilly's Retevmo Gets FDA Accelerated Approval for Kids With RET-altered Thyroid Cancer, Solid Tumors, from 1:45PM ET on Wednesday May 29, 2024 by MT Newswires

DJ Nvidia Stock Jumped After Stock-Split News. These 14 Names Could Be Next. -- Barrons.com, from 10:52AM ET on Wednesday May 29, 2024 by Dow Jones

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases, from 6:00AM ET on Wednesday May 29, 2024 by Dow Jones

Peers Headlines

May 31, 2024

Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal, from 4:45PM ET on Friday May 31, 2024 by MT Newswires

Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints, from 9:23AM ET on Friday May 31, 2024 by MT Newswires

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday, from 9:19AM ET on Friday May 31, 2024 by MT Newswires

Novartis Confirms Long-term Safety, Efficacy of Skin Disease Drug, from 9:03AM ET on Friday May 31, 2024 by MT Newswires

Sector Update: Health Care, from 8:58AM ET on Friday May 31, 2024 by MT Newswires

AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate, from 4:34AM ET on Friday May 31, 2024 by MT Newswires

May 30, 2024

US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected, from 4:09PM ET on Thursday May 30, 2024 by MT Newswires

Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar, from 3:46PM ET on Thursday May 30, 2024 by MT Newswires

Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target, from 8:23AM ET on Thursday May 30, 2024 by MT Newswires

Goldman Sachs Starts AstraZeneca With Buy Rating, $97 Price Target, from 8:14AM ET on Thursday May 30, 2024 by MT Newswires